Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

Table 5 Baseline hematological prognostic indicators markers for patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1immunotherapy, mean ± SD

Characteristics	Stats	Normal range
Height (cm)	168.3 ± 8.0	140-190
Weight (kg)	67.7 ± 12.0	40-100
ALLC (109/L)	6.0 ± 1.9	3.5-9.5
RDW (%)	15.2 ± 3.8	11.6-14.8
PLT (109/L)	178.2 ± 63.7	125-350
ANC (109/L)	4.1 ± 1.4	1.8-6.3
ALC (109/L)	1.4 ± 0.5	1.1-3.2
AMC (109/L)	0.4 ± 0.1	0.1-0.6
AEC (109/L)	0.2 ± 0.2	0.02-0.52
ALB (g/L)	41.4 ± 4.0	40-55
LDH (IU/L)	240.0 ± 154.9	109-245
FIB (g/L)	3.6 ± 0.7	2-4
Dimer (ng/ml)	257.3 ± 647.3	0-500
CEA (ng/mL), n (%)	6 (24.0%)	0-5
	19 (76.0%)	-
CA199 (IU/mL), n (%)	13 (52.0%)	0-37
	12 (48.0%)	-

ALLC: Absolute leukocyte count; RDW: Red blood cell distribution width; PLT: Platelet; ANC: Absolute neutrophil count; ALC: Absolute lymphocyte count; AMC: Absolute monocyte count; AEC: Absolute eosinophil count; ALB: Albumin; LDH: Lactate dehydrogenase; FIB: Fibrinogen; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199.